CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 15 enrolled
Drug / intervention
atazanavir/ritonavir +1 moredrug
Likely dose
atazanavir/ritonavir 300mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00413153
NCT00413153N/ACompleted
CompareCT.gov

Metabolic Effects of Switching Kaletra to Boosted Reyataz

Massachusetts General Hospital·interventional·Posted Dec 19, 2006·Updated Mar 9, 2010

In Brief

A clinical study evaluating atazanavir/ritonavir and lopinavir/ritonavir for HIV Infections. Completed, enrolled 15 participants across 1 site.

Detailed Summary

To study the effects of switching from Kaletra to Boosted Reyataz on glucose, lipids and fat in HIV-infected patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesUnited States
CollaboratorsBristol-Myers Squibb

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 19, 2006
Enrollment StartMay 1, 2006
Primary CompletionDec 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 19.5 years ago

Interventions

atazanavir/ritonavirdrug

atazanavir 300mg + ritonavir 100mg once daily

lopinavir/ritonavirdrug

patient remains on their pre-study dose of lopinavir/ritonavir